Therapies in early development for the treatment of opiate addiction

Bibliography

• Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician 2014;17:E119-28
   PubMed Web of Science ®Google Scholar
• Reece AS, Hulse GK. Impact of lifetime opioid exposure on arterial stiffness and vascular age: cross-sectional and longitudinal studies in men and women. BMJ Open 2014;4:1-19
   Web of Science ®Google Scholar
• Ghitza UE. Needed relapse-prevention research on novel framework (ASPIRE Model) for substance use disorders treatment. Front Psychiatry 2015;6:37
   Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;3:CD002209
   PubMed Web of Science ®Google Scholar
• Potter JS, Dreifuss JA, Marino EN, et al. Themulti-site Prescription Opioid Addiction Treatment Study: 18-month outcomes. J Subst. Abuse Treat 2015;48:62-9
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol 2008;59:29-53
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Randall D, Hall W, et al. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug Alcohol Depend 2009;105:9-15
   PubMed Web of Science ®Google Scholar
• Reece AS, Hulse GK. Reduction in arterial stiffness and vascular age by naltrexone-induced interruption of opiate agonism. BMJ Open 2013;3(3):e002610
   PubMed Web of Science ®Google Scholar
• Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs 2010;42:339-46
   PubMed Web of Science ®Google Scholar
• Roux P, Sullivan MA, Cohen J, et al. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain 2013;154:1442-8
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Dunn KE, Saulsgiver K, et al. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 2013;70:1347-54
   Google Scholar
• Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther 2011;89:443-9
   PubMed Web of Science ®Google Scholar
• Nasser AF, Heidbreder C, Gomeni R, et al. A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet 2014;53:813-24
   PubMed Web of Science ®Google Scholar
• Fischer A, Jönsson M, Hjelmström P. Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers. Drug Dev Ind Pharm 2015;41:79-84
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;16:CD002207
   Google Scholar
• Lofwall MR, Babalonis S, Nuzzo PA, et al. Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial. Drug Alcohol Depend 2013;133:188-97
   PubMed Web of Science ®Google Scholar
• Colquhoun RM. Open label trial of naltrexone implants: measuring blood serum levels of naltrexone. Subst Abuse 2013;7:75-84
   PubMedGoogle Scholar
• Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction 2013;108:1628-37
   PubMed Web of Science ®Google Scholar
• Di Paola A, Lincoln T, Skiest DJ, et al. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials 2014;39:256-68
   PubMed Web of Science ®Google Scholar
• Lee JD, McDonald R, Grossman E, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction 2015;110:1008-14
   PubMed Web of Science ®Google Scholar
• Kunøe N, Lobmaier P, Ngo H, et al. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. Br J Clin Pharmacol 2014;77:264-71
   PubMed Web of Science ®Google Scholar
• Larney S, Gowing L, Mattick RP, et al. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug Alcohol Rev 2014;33:115-28
   PubMed Web of Science ®Google Scholar
• Goonoo N, Bhaw-Luximon A, Ujoodha R, et al. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems. J Control Release 2014;183:154-66
   PubMed Web of Science ®Google Scholar
• Fields HL, Margolis EB. Understanding opioid reward. Trends Neurosci 2015;38:217-25
   PubMed Web of Science ®Google Scholar
• Ting-A-Kee R, Vargas-Perez H, Mabey JK, et al. Ventral tegmental area GABA neurons and opiate motivation. Psychopharmacology 2013;227:697-709
   PubMed Web of Science ®Google Scholar
• Mameli M, Bellone C, Brown MT, et al. Cocaine inverts rules for synaptic plasticity of glutamate transmission in the ventral tegmental area. Nat Neurosci 2011;14:414-16
   PubMed Web of Science ®Google Scholar
• Lane DA, Lessard AA, Chan J, et al. Region-specific changes in the subcellular distribution of AMPA receptor GluR1 subunit in the rat ventral tegmental area after acute or chronic morphine administration. J Neurosci 2008;28:9670-81
   PubMed Web of Science ®Google Scholar
• Wang Z, Yan P, Hui T, et al. Epigenetic upregulation of PSD-95 contributes to the rewarding behavior by morphine conditioning. Eur J Pharmacol 2014;732:123-9
   PubMed Web of Science ®Google Scholar
• Befort K. Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Front Pharmacol 2015;6:6
   PubMed Web of Science ®Google Scholar
• Heidbreder C. Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of substance use disorders. Naunyn Schmiedebergs Arch Pharmacol 2013;386:167-76
   PubMed Web of Science ®Google Scholar
• Almeida-Santos AF, Gobira PH, Souza DP, et al. The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice. Eur J Pharmacol 2014;742:139-44
   PubMed Web of Science ®Google Scholar
• Lai M, Chen W, Zhu H, et al. Low dose risperidone attenuates cue-induced bu not heroin-induced resintatement of heroin seeking in an animal model of relapse. Int J Neursopyschopharmcol 2013;16:1569-75
   PubMed Web of Science ®Google Scholar
• Meng S, Quan W, Qi X, et al. Effect of baclofen on morphine-induced conditioned place preference, extinction, and stress-induced reinstatement in chronically stressed mice. Psychopharmacology (Berl) 2014;231:27-36
   PubMed Web of Science ®Google Scholar
• Ramshini E, Alaei H, Reisi P, et al. The role of GABAB receptors in morphine self-administration. Int J Prev Med 2013;4:158-64
   PubMedGoogle Scholar
• Bao YH, Zhou QH, Chen R, et al. Gabapentin attenuates morphine tolerance through interleukin-10. Neuroreport 2014;25:71-6
   PubMed Web of Science ®Google Scholar
• Sanders NC, Mancino MJ, Gentry WB, et al. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol 2013;21:294-302
   PubMed Web of Science ®Google Scholar
• Hasanein P, Shakeri S. Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats. Eur J Pharmacol 2014;742:113-17
   PubMed Web of Science ®Google Scholar
• Everitt BJ. Neural and psychological mechanisms underlying compulsive drug seeking habits and drug memories–indications for novel treatments of addiction. Eur J Neurosci 2014;40:2163-82
   PubMed Web of Science ®Google Scholar
• Portugal GS, Al-Hasani R, Fakira AK, et al. Hippocampal long-term potentiation is disrupted during expression and extinction but is restored after reinstatement of morphine place preference. J Neurosci 2014;34:527-38
   PubMed Web of Science ®Google Scholar
• Shen HW, Scofield MD, Boger H, et al. Synaptic glutamate spillover due to impaired glutamate uptake mediates heroin relapse. J Neurosci 2014;34:5649-57
   PubMed Web of Science ®Google Scholar
• Ahmadi S, Golbaghi H, Azizbeigi R, et al. N-methyl-D-aspartate receptors involved in morphine-induced hyperalgesia in sensitized mice. Eur J Pharmacol 2014;737:85-90
   PubMed Web of Science ®Google Scholar
• Wang WS, Chen ZG, Liu WT, et al. Dorsal hippocampal NMDA receptor blockade impairs extinction of naloxone-precipitated conditioned place aversion in acute morphine-treated rats by suppressing ERK and CREB phosphorylation in the basolateral amygdala. Br J Pharmacol 2015;172:482-91
   PubMed Web of Science ®Google Scholar
• Fakira AK, Portugal GS, Carusillo B, et al. Increased small conductance calcium-activated potassium type 2 channel-mediated negative feedback on N-methyl-D-aspartate receptors impairs synaptic plasticity following context-dependent sensitization to morphine. Biol Psychiatry 2014;75:105-14
   PubMed Web of Science ®Google Scholar
• Ma YY, Yu P, Guo CY, et al. Effects of ifenprodil on morphine-induced conditioned place preference and spatial learning and memory in rats. Neurochem Res 2011;36:383-91
   PubMed Web of Science ®Google Scholar
• Kao JH, Huang EY, Tao PL. NR2B subunit of NMDA receptor at nucleus accumbens is involved in morphine rewarding effect by siRNA study. Drug Alcohol Depend 2011;118:366-74
   PubMed Web of Science ®Google Scholar
• Bisaga A, Sullivan MA, Glass A, et al. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. J Subst Abuse Treat 2014;46:546-52
   PubMed Web of Science ®Google Scholar
• Ding X, Liang J, Zheng X, et al. Altered phosphorylation of GluA1 in the striatum is associated with locomotor sensitization induced by exposure to increasing doses of morphine. Eur J Pharmacol 2013;702:294-301
   PubMed Web of Science ®Google Scholar
• Rutten K, Van Der Kam EL, De Vry J, et al. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference induced by various addictive and non-addictive drugs in rats. Addict Bio 2011;16:108-15
   PubMed Web of Science ®Google Scholar
• Jenda M, Gawel K, Marszalek M, et al. AMN082, a metabotropic glutamate receptor 7 allosteric agonist, attenuates locomotor sensitization and cross-sensitization induced by cocaine and morphine in mice. Prog Neuropsychopharmacol Biol Psychiatry 2015;57:166-75
   PubMed Web of Science ®Google Scholar
• Ma P, Liu H, Li H, et al. Involvement of the insular nitric oxide signaling pathway in the expression of morphine-induced conditioned place preference in rats. Neuroreport 2014;25:641-6
   PubMed Web of Science ®Google Scholar
• Karami M, Rahimpour M, Karimi S, et al. Nitric oxide in central amygdala potentiates expression of conditioned withdrawal induced by morphine. Indian J Pharmacol 2014;46:57-62
   PubMed Web of Science ®Google Scholar
• Mansouri MT, Naghizadeh B, Ghorbanzadeh B. Ellagic acid enhances morphine analgesia and attenuates the development of morphine tolerance and dependence in mice. Eur J Pharmacol 2014;741:272-80
   PubMed Web of Science ®Google Scholar
• Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 2013;248:637-54
   PubMed Web of Science ®Google Scholar
• Katsidoni V, Anagnostou I, Panagis G. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol 2013;18:286-96
   PubMed Web of Science ®Google Scholar
• Maguire DR, Yang W, France CP. Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration. J Pharmacol Exp Ther 2013;345:354-62
   PubMed Web of Science ®Google Scholar
• Muldoon PP, Jackson KJ, Perez E, et al. The alpha3beta4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies. Br J Pharmacol 2014;171:3845-57
   PubMed Web of Science ®Google Scholar
• Hooten WM, Warner DO. Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial. Addict Behav 2015;42:69-72
   PubMed Web of Science ®Google Scholar
• Gawel K, Labuz K, Jenda M, et al. Influence of cholinesterase inhibitors, donepezil and rivastigmine on the acquisition, expression, and reinstatement of morphine-induced conditioned place preference in rats. Behav Brain Res 2014;268:169-76
   PubMed Web of Science ®Google Scholar
• Ackermann S, Hartmann F, Papassotiropoulos A, et al. Associations between basal cortisol levels and memory retrieval in healthy young individuals. J Cogn Neurosci 2013;25:1896-907
   PubMed Web of Science ®Google Scholar
• Schank JR. The neurokinin-1 receptor in addictive processes. J Pharmacol Exp Ther 2014;351:2-8
   PubMed Web of Science ®Google Scholar
• Jones JD, Speer T, Comer SD, et al. Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone. Am J Drug Alcohol Abuse 2013;39:86-91
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Johnson KW, Pavlicova M, et al. The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol 2015; in press
   PubMedGoogle Scholar
• Crist RC, Clarke TK, Ang A, et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology 2013;38:2003-10
   PubMed Web of Science ®Google Scholar
• Barratt DT, Coller JK, Hallinan R, et al. ABCB1 haplotype and OPRM1 118A>G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmgenomics Pers Med 2012;5:53-62
   PubMedGoogle Scholar
• Gerra G, Somaini L, Leonardi C, et al. Association between gene variants and response to buprenorphine maintenance treatment. Psychiatry Res 2014;215:202-7
   PubMed Web of Science ®Google Scholar
• Nielsen DA, Utrankar A, Reyes JA, et al. Epigenetics of drug abuse: predisposition or response. Pharmacogenomics 2012;13:1149-60
   PubMed Web of Science ®Google Scholar
• Nielsen DA, Hamon S, Yuferov V, et al. Ethnic diversity of DNA methylation in the OPRM1 promoter region in lymphocytes of heroin addicts. Hum Genet 2010;127:639-49
   PubMed Web of Science ®Google Scholar
• Chorbov VM, Todorov AA, Lynskey MT, et al. Elevated levels of DNA methylation at the OPRM1 promoter in blood and sperm from male opioid addicts. J Opioid Manag 2011;7:258-64
   PubMedGoogle Scholar
• Fragou D, Zanos P, Kouidou S, et al. Effect of chronic heroin and cocaine administration on global DNA methylation in brain and liver. Toxicol Lett 2013;218:260-5
   PubMed Web of Science ®Google Scholar
• Chao MR, Fragou D, Zanos P, et al. Epigenetically modified nucleotides in chronic heroin and cocaine treated mice. Toxicol Lett 2014;229:451-7
   PubMed Web of Science ®Google Scholar
• Koo JW, Mazei-Robison MS, LaPlant Q, et al. Epigenetic basis of opiate suppression of Bdnf gene expression in the ventral tegmental area. Nat Neurosci 2015;18:415-22
   PubMed Web of Science ®Google Scholar
• Pintér-Kübler B, Ferenczi S, Núnez C, et al. Differential changes in expression of stress- and metabolic-related neuropeptides in the rat hypothalamus during morphine dependence and withdrawal. PLoS ONE 2013;8:e67027
   PubMed Web of Science ®Google Scholar
• Noble F, Benturquia N, Crete D, et al. Relationship between vulnerability to reinforcing effects of morphine and activity of the endogenous cholecystokinin system in Lewis and Fischer rats. Addict Biol 2012;17:528-38
   PubMed Web of Science ®Google Scholar
• Park PE, Schlosburg JE, Vendruscolo LF, et al. Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hiperalgesia. Addict Biol 2015;20:275-84
   PubMed Web of Science ®Google Scholar
• Park PE, Vendruscolo LF, Schlosburg JE, et al. Corticotropin-releasing factor (CRF) and alpha 2 adrenergic receptors mediate heroin withdrawal-potentiated startle in rats. Int J Neuropsychopharmacol 2013;16:1867-75
   PubMed Web of Science ®Google Scholar
• Martínez-Laorden E, García-Carmona JA, Baroja-Mazo A, et al. Corticotropin-releasing factor (CRF) receptor-1 is involved in cardiac noradrenergic activity observed during naloxone-precipitated morphine withdrawal. Br J Pharmacol 2014;171:688-700
   PubMed Web of Science ®Google Scholar
• Navarro-Zaragoza J, Martínez-Laorden E, Mora L, et al. Cardiac adverse effects of naloxone-precipitated morphine withdrawal on right ventricle: role of corticotropin-releasing factor (CRF) 1 receptor. Toxicol Appl Pharmacol 2014;275:28-35
   PubMed Web of Science ®Google Scholar
• Rouibi K, Contarino A. The corticotropin-releasing factor receptor-2 mediates the motivational effect of opiate withdrawal. Neuropharmacology 2013;73:41-7
   PubMed Web of Science ®Google Scholar
• Elhabazi K, Trigo JM, Mollereau C, et al. Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments. Br J Pharmacol 2012;165:424-35
   PubMed Web of Science ®Google Scholar
• Ghazal P, Ciccocioppo R, Ubaldi M. Morphine dependence is associated with changes in neuropeptide S receptor expression and function in rat brain. Peptides 2013;46:6-12
   PubMed Web of Science ®Google Scholar
• Wu P, Shi HS, Luo YX, et al. Neuropeptide trefoil factor 3 attenuates naloxone-precipitated withdrawal in morphine-dependent mice. Psychopharmacology (Berl) 2014;231:4659-68
   PubMed Web of Science ®Google Scholar
• Desai SJ, Upadhya MA, Subhedar NK, et al. NPY mediates reward activity of morphine, via NPY Y1 receptors, in the nucleus accumbens shell. Behav Brain Res 2013;247:79-91
   PubMed Web of Science ®Google Scholar
• Barbier E, Vendruscolo LF, Schlosburg JE, et al. The NK1 receptor antagonist L822429 reduces heroin reinforcement. Neuropsychopharmacology 2013;38:976-84
   PubMed Web of Science ®Google Scholar
• Sukhtankar DD, Lagorio CH, Ko MC. Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats. Eur J Pharmacol 2014;745:182-9
   PubMed Web of Science ®Google Scholar
• Lipták N, Dochnal R, Csabafi K, et al. Obestatin prevents analgesic tolerance to morphine and reverses the effects of mild morphine withdrawal in mice. Regul Pept 2013;186:77-82
   PubMed Web of Science ®Google Scholar
• Richardson KA, Aston-Jones G. Lateral hypothalamic orexin/hypocretin neurons that project to ventral tegmental area are differentially activated with morphine preference. J Neurosci 2012;32:3809-17
   PubMed Web of Science ®Google Scholar
• Schmeichel BE, Barbier E, Misra KK, et al. Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats. Neuropsychopharmacology 2014;40:1123-9
   Web of Science ®Google Scholar
• Tabaeizadeh M, Motiei-Langroudi R, Mirbaha H, et al. The differential effects of OX1R and OX2R selective antagonists on morphine conditioned place preference in naïve versus morphine-dependent mice. Behav Brain Res 2013;237:41-8
   PubMed Web of Science ®Google Scholar
• Zarepour L, Fatahi Z, Sarihi A, et al. Blockade of orexin-1 receptors in the ventral tegmental area could attenuate the lateral hypothalamic stimulation-induced potentiation of rewarding properties of morphine. Neuropeptides 2014;48:179-85
   PubMed Web of Science ®Google Scholar
• Ahmadi-Soleimani SM, Ghaemi-Jandabi M, Azizi H, et al. Orexin type 1 receptor antagonism in Lateral Paragigantocellularis nucleus attenuates naloxone precipitated morphine withdrawal symptoms in rats. Neurosci Lett 2014;558:62-6
   PubMed Web of Science ®Google Scholar
• Zanos P, Georgiou P, Wright SR, et al. The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice. Neuropsychopharmacology 2014;39:855-65
   PubMed Web of Science ®Google Scholar
• Campbell LA, Avdoshina V, Rozzi S, et al. CCL5 and cytokine expression in the rat brain: differential modulation by chronic morphine and morphine withdrawal. Brain Behav Immun 2013;34:130-40
   PubMed Web of Science ®Google Scholar
• Nguyen TL, Kwon SH, Hong SI, et al. Transient receptor potential vanilloid type 1 channel may modulate opioid reward. Neuropsychopharmacology 2014;39:2414-22
   PubMed Web of Science ®Google Scholar
• Yang HY, Wu ZY, Wood M, et al. Hydrogen sulfide attenuates opioid dependence by suppression of adenylate cyclase/cAMP pathway. Antioxid Redox Signal 2014;20:31-41
   PubMed Web of Science ®Google Scholar
• Spahn V, Fischer O, Endres-Becker J, et al. Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner. Pain 2013;154:598-608
   PubMed Web of Science ®Google Scholar
• Theberge FR, Li X, Kambhampati S, et al. Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving. Biol Psychiatry 2013;73:729-37
   PubMed Web of Science ®Google Scholar
• Mattioli TA, Leduc-Pessah H, Skelhorne-Gross G, et al. Toll-like receptor 4 mutant and null mice retain morphine-induced tolerance, hyperalgesia, and physical dependence. PLoS ONE 2014;9:e97361
   PubMed Web of Science ®Google Scholar
• Ghavimi H, Azarfardian A, Maleki-Dizaji N, et al. Acute administration of pioglitazone attenuates morphine withdrawal syndrome in rat: a novel role of pioglitazone. Drug Res 2015;65:113-18
   Google Scholar
• Javadi S, Ejtemaeimehr S, Keyvanfar HR, et al. Pioglitazone potentiates development of morphine-dependence in mice: possible role of NO/cGMP pathway. Brain Res 2013;1510:22-37
   PubMed Web of Science ®Google Scholar
• de Guglielmo G, Melis M, De Luca MA, et al. PPAR gamma activation attenuates opioid consumption and modulates mesolimbic dopamine transmission. Neuropsychopharmacology 2015;40:927-37
   PubMed Web of Science ®Google Scholar